Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-17
1996-12-10
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, A61K 3144, A61K 31505
Patent
active
055831400
ABSTRACT:
Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo[2.2.1]hept-5-ene and 2-azabicyclo[2.2.2]oct-5-ene compounds.
REFERENCES:
patent: 3870794 (1975-03-01), Hutchinson et al.
patent: 4342762 (1982-08-01), Budai et al.
patent: 4578394 (1986-03-01), Allen et al.
patent: 4680172 (1987-07-01), Leeson
patent: 4786646 (1988-11-01), Guthrie et al.
patent: 4916145 (1990-04-01), Tilley et al.
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 4965074 (1990-10-01), Leeson
patent: 5110933 (1992-05-01), Berlin et al.
patent: 5210076 (1993-05-01), Berliner et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5219872 (1993-06-01), Galliani et al.
patent: 5219873 (1993-06-01), Galliani et al.
patent: 5225567 (1993-07-01), Moon et al.
patent: 5227391 (1993-07-01), Caldwell et al.
patent: 5242935 (1993-09-01), Lippiello et al.
patent: 5262427 (1993-11-01), Nielson et al.
patent: 5346906 (1994-09-01), Baker et al.
Kelly, T. et al., "Maxonine: Structure Correction and Synthesis", Tetrahedron Letters, vol. 34, No. 39, pp. 6173-6176 (1993).
Leete, E. et al. "Formation of 5-Fluoronicotine from 5-Fluoronicotinic Acid in Nicotiana Tabacum*", Phytochemistry, 1971, vol. 10, pp. 2687 to 2692.
Lynch, B. et al. "Pyrazolo [3,4-b]pyridines: Syntheses, reactions, and nuclear magnetic resonance spectra", Can. J. Chem. 66, 420 (1988).
Rubtsov M. et al., Translated from Zhurnal Obshchei Khimii, "Hofmann Cleavage of 6,9-diazoniadispiro-[5.2.5.2]hexadecane dichloride with methanolic potassium hydroxide", vol. 35, No. 4, pp. 621-628 (Apr. 1965).
Sadikov, A. et al., Translated from Zhurnal Obshchei Khimii, "Syntheses Based on Anabasine", vol. 33, No. 10, pp. 3417-3420 (Oct. 1963).
Seeman, J. et al., Anal. Chem., "Enantiomeric Resolution and Chiral Recognition of Racemic Nicotine and Nicotine Analogues by .beta.-Cyclodextrin Complexation. Structure-Enantiomeric Resolution Relationships in Host-Guest Interactions", 60, 2120-2127 (1988).
Baron, J., "Cigarette smoking and Parkinson's disease", Neurology, vol. 36, pp. 1490-1496 (1986).
Benwell, M. et al., "Evidence that Tobacco Smoking Increases the Density of (-)-[.sup.3 H] Nicotine Binding Sites in Human Brain", Journal of Neurochemistry, vol. 50, pp. 1243-1247 (1988).
Clark, P. et al., "Electrophysiological actions of nicotine on substantia nigra single units", Br. J. Pharm., vol. 85, pp. 827-835 (1985).
Decina, P. et al., "Cigarette Smoking and Neuroleptic-Induced Parkinsonism", Biol. Psychiatry, vol. 28, pp. 502-508 (1990).
Giacobini, E., "Pharmacotherapy of Alzheimer's Disease: New Drugs and Novel Strategies", Alzheimer's Disease: Advances in Clinical and Basic Research, S61, pp. 529-538 (1993).
Giacobini, E., "New Cholinesterase Inhibitors for Treatment of Alzheimer's Disease", Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, S80, pp. 627-631 (1991).
Giacobini, E., "Cholinergic Receptors in Human Brain: Effects of Aging and Alzheimer's Disease", Journal of Neuroscience Research, vol. 27, pp. 548-560 (1990).
Giacobini, E., "The Second Generation of Cholinesterasse Inhibitors: Pharmacological Aspects", Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al. Boxton:Birkhauser (1991).
Giacobini, E. et al., "Toward a Third Generation of Cholinesterase Inhibitors", Pharmacological Basis of Cholinergic Therapy of Alz. Dis., Eds., Becker, R. et al., Boxton:Birkhauser, (1991).
Hall, G. et al., "Effects of Nicotine on the Release of .sup.3 H-Noradrenaline from the Hypothalamus", Biochemical Pharmacology, vol. 21, pp. 1829-1838 (1972).
Harsing, L. et al., "Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization", Journal of Neurochemistry, vol. 59, pp. 48-54 (1993).
Hery, F. et al., "Control of the Release of Newly Synthetized .sup.3 H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat hypothalamic Slices", Arch. Int. Pharmacodyn. Ther., vol. 296, pp. 91-97 (1977).
Janson, A. et al., "Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopa neurons in the male rat", Progress in Brain Research, vol. 79, pp. 257-265 (1989).
Jarvik, M. "Beneficial effects of nicotine", British Journal of Addiction, vol. 86, pp. 571-575 (1991).
Jones, A. et al., "Alzheimer's Disease: Clinical and Pathological Characteristics", Intern. J. Neuroscience, vol. 50, pp. 147-168 (1990).
Marks, M. et al., "Effects of Chronic Nicotine Infusion on Tolerance Development and Nicotinic Receptors", The Journal of Pharmacology and Experimental Therapeutics, vol. 226, pp. 817-825 (1983).
Hughes, "Proceedings from Intl. Symp. Nic.", S40 (1994).
New house, P. et al., "Intravenous nicotine in Alzheimer's disease: a pilot study", Psychopharmacology, vol. 95, pp. 171-175 (1988).
Nordberg, A. et al., "The role of nicotinic receptors in the pathophysiology of Alzheimer's disease", Progress in Brain Research, vol. 79, pp. 353-362 (1989).
Onaivi, E. et al., "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats", Life Sciences, vol. 54, pp. 193-202 (1994).
Perry E., "The Cholinergic Hypothesis-Ten Years On", British Medical Bulletin, vol. 42, pp. 63-69 (1986).
Pomponi, M. et al., "Present state and future development of the therapy of Alzheimer disease", Aging, vol. 2(2), pp. 125-153 (1990).
Rapier, C. et al., "Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation", Journal of Neurochemistry, vol. 50, pp. 1123-1130 (1988).
Rinne, J. et al., "A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease", Brain Research, vol. 547, pp. 167-170 (1991).
Rowell, P., "Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System", Adv. Behav. Biol., vol. 31, pp. 191-208 (1987).
Rowell, P. et al., "Nicotinic Stimulation of [.sup.3 H]Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes", Journal of Neurochemistry, vol. 43, pp. 1593-1598 (1984).
Sahakian, B. et al., "The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients ith Dementia of the Alzheimer Type", British Journal of Psychiatry, vol. 154, pp. 797-800 (1989).
Sanberg, P. et al., "Nicotine Potentiation of Haloperidol-Induced Catalepsy: Striatal Mechanisms", Pharmacology Biochemistry and Behavior, vol. 46, pp. 303-307 (1993).
Sandor, N. et al., "Effect of nicotine on dopaminergic-cholinergic interaction in the striatum", Brain Research, vol. 567, pp. 313-316 (1991).
Sherwood, Human Psychopharm., vol. 8, pp. 155-184 (1993).
Sjak-Shie, N. et al., "Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and [.sup.3 H] GABA uptake in nucleus basalis lesioned rats", Brain Research, vol. 624, pp. 295-298 (1993).
Smith, C. et al., "Nicotine, Parkinson's and Alzheimer's Disease", Rev. in Neuroscience, vol. 3, pp. 25-43 (1992).
Toth, E. et al., "Effect of Nicotine on Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid", Neurochemical Research, vol. 17(3), pp. 265-271 (1992).
van Duijan, C. et al., "Relation between nicotine intake and Alzheimer's disease", BMJ, vol. 302, pp. 1491-1494 (1991).
Vizi, E., "Acetylcholine release from guinea-pig ileum by parasympathetic ganglion stimulants and gastrin-like polypeptides", British Journal Pharmacology, vol. 47, pp. 765-777 (1973).
Physicians' Desk Reference, 48 Edition, pp. 899-903 (1994), "Sinemet".
Physicians' Desk Reference, 48 Edition, pp. 2067-2069 (1994), "Parlodel".
Physicians' Desk Reference, 48 Edition, pp. 2309-2311 (1994), "Eldepryl".
Hodges, H. et al., "Nicotine as a Tool to Characterize the Role of the Forebrain Cholinergic
Bencherif Merouane
Caldwell William S.
Dull Gary M.
Lippiello Patrick M.
Cintins Marianne M.
Jarvis William R. A.
LandOfFree
Pharmaceutical compositions for the treatment of central nervous does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for the treatment of central nervous, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for the treatment of central nervous will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-424431